Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canbridge PharmaceuticalsFRA:MF1 48 Cash Ratio is 0.15 as of Dec. 2025, which is 61% below its 10-year median of 0.38. GuruFocus rates FRA:MF1 with a GF Score™ of 48/100 and a GF Value™ of €0.03. The stock has 7 warning signs investors should review. Among 1,381 Biotechnology companies, Canbridge Pharmaceuticals ranks worse than 92.98% on this metric.
Canbridge Pharmaceuticals has a Cash Ratio of 0.15. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Canbridge Pharmaceuticals's Cash Ratio or its related term are showing as below:
FRA:MF1'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.38 Max: 4.01
Current: 0.15
During the past 7 years, Canbridge Pharmaceuticals's highest Cash Ratio was 4.01. The lowest was 0.02. And the median was 0.38.
FRA:MF1's Cash Ratio is ranked worse than 92.98% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs FRA:MF1: 0.15
Canbridge Pharmaceuticals (FRA:MF1) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Canbridge Pharmaceuticals Cash Ratio Related Terms
Canbridge Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MF1 vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (FRA:MF1) has a Cash Ratio of 0.15 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Canbridge Pharmaceuticals and its competitors. This is 61% below median its historical median of 0.38. Over the past decade, Canbridge Pharmaceuticals' Cash Ratio has ranged from 0.02 to 4.01. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #1284 out of 1381 companies in the Biotechnology industry, placing it in the top 93%.
Is Canbridge Pharmaceuticals' Cash Ratio too high?
Canbridge Pharmaceuticals' current Cash Ratio of 0.15 is 61% below median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 4.01. The Biotechnology industry median Cash Ratio is 2.96. Canbridge Pharmaceuticals' value of 0.15 is 94.9% below this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #1284 out of 1381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #1284 out of 1381 companies for Cash Ratio. This places Canbridge Pharmaceuticals in the lower half of its industry. The industry median Cash Ratio is 2.96. Canbridge Pharmaceuticals' value of 0.15 is 94.9% below this benchmark. Historically, Canbridge Pharmaceuticals' own Cash Ratio has ranged from 0.02 to 4.01 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 2.96, Canbridge Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current Cash Ratio of 0.15 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Canbridge Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current Cash Ratio is 0.15, which is 61% below median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current Cash Ratio of 0.15. The stock's GF Value™ is €0.03, compared to a current price of €0.17 — trading 476.7% above its estimated fair value. The current Cash Ratio is 0.15, which is 61% below median its 10-year median of 0.38 and 94.9% below the Biotechnology industry median of 2.96. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current Cash Ratio is 0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.17 is trading 476.7% above its estimated GF Value™ of €0.03.
Key valuation signals for FRA:MF1:
Cash Ratio: 0.15 (61% below median its 10-year median of 0.38)
GF Value™: €0.03 vs. price of €0.17 (476.7% above fair value)
Industry Position: 94.9% below the Biotechnology median (#1284 of 1381)
No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for FRA:MF1
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MF1 has been successfully added to your 
